

Proteinase Activated Receptor 2 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/P124198B448AEN.html>

Date: December 2019

Pages: 52

Price: US\$ 3,500.00 (Single User License)

ID: P124198B448AEN

Abstracts

Proteinase Activated Receptor 2 - Pipeline Review, H2 2019

SUMMARY

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Protease activated receptor 2 (PAR2) also known as coagulation factor II (thrombin) receptor-like 1 (F2RL1) is a protein encoded by the F2RL1 gene. PARs (protease-activated receptors) are G-protein-coupled receptors for proteases from the circulation, inflammatory cells and epithelial tissues. PAR2 plays an important role in inflammation and pain. Pancreatic (trypsin I and II) and extrapancreatic (trypsin IV) trypsins, mast cell tryptase and coagulation factors VIIa and Xa cleave and activate PAR 2.

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Dermatology, Respiratory, Cardiovascular, Genito Urinary System And Sex Hormones, Metabolic Disorders and Oncology which include indications Atopic Dermatitis (Atopic Eczema), Inflammation, Non-Alcoholic Steatohepatitis (NASH), Celiac Disease, Idiopathic Pulmonary Fibrosis, Inflammatory Bowel Disease, Kidney Fibrosis, Obesity, Psoriasis, Pulmonary Fibrosis, Pulmonary Hypertension and Type 2 Diabetes.

The latest report Proteinase Activated Receptor 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1)

The report reviews Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics and

enlists all their major and minor projects

The report assesses Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Proteinase

Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) -

Overview

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) -

Companies Involved in Therapeutics Development

Hadasit Medical Research Services and Development Ltd

Innovate Biopharmaceuticals Inc

Oasis Pharmaceuticals LLC

PeptiDream Inc

Sosei Heptares

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Drug Profiles

GB-88 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Iarazotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize PAR2 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-2pal18S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Antagonize PAR-1 and PAR-2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PZ-235 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize PAR2 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Dormant Products

Proteinase Activated Receptor 2 (PAR2 or Coagulation Factor II Receptor Like 1 or G Protein Coupled Receptor 11 or Thrombin Receptor Like 1 or GPR11 or F2RL1) - Product Development Milestones

Featured News & Press Releases

Aug 13, 2019: Innovate Biopharmaceuticals announces first patient dosed in the first phase 3 clinical trial for patients with celiac disease

Jul 15, 2019: Innovate Biopharmaceuticals announces corporate update and expected date for second quarter earnings release

Jun 24, 2019: Innovate Biopharmaceuticals expands its management team with the addition of Ed Sitar as Its Chief Financial Officer

Jun 10, 2019: Innovate Biopharmaceuticals announces the start of the first phase 3 clinical trial in Celiac Disease

May 20, 2019: Innovate Biopharmaceuticals announces presentation of three posters focusing on the molecular biology and pharmacology of Larazotide at the 2019 Digestive Disease Week Conference in San Diego

Apr 29, 2019: Innovate Biopharmaceuticals shows Larazotide is the first drug, with its novel mechanism of action of re-normalizing the intestinal barrier, to demonstrate improvements in validated NASH biomarkers and endpoints in synergy with obeticholic acid, an FXR ag

Apr 11, 2019: Innovate Biopharmaceuticals presents oral poster at European Association for the Study of the Liver (EASL) demonstrating positive effect of larazotide on reduced intestinal permeability in a NASH preclinical study

Apr 02, 2019: Innovate Biopharmaceuticals to announce first quarter 2019 financial results and to provide operational progress updates on April 29, 2019

Mar 19, 2019: Innovate Biopharmaceuticals reports financing to initiate the first phase 3 clinical trial in celiac disease

Feb 25, 2019: Innovate Biopharmaceuticals announces acceptance of three abstracts focusing on the molecular biology and pharmacology of Larazotide for the 2019 Digestive Disease Week Conference

Dec 17, 2018: Innovate Biopharmaceuticals plans to commence the first ever phase 3 registration trial in celiac disease in 1H 2019 and announce top-line NASH data with drug combinations by EASL 2019

Nov 12, 2018: Sanyal Biotechnology and Innovate Biopharmaceuticals present data at AASLD validating a proprietary Leaky Gut assay demonstrating reduced intestinal permeability with Larazotide Acetate treatment in a NASH preclinical study

Oct 29, 2018: Innovate Biopharmaceuticals announces positive effect of Larazotide Acetate on reducing intestinal permeability in a NASH preclinical study

May 17, 2018: Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C.

May 09, 2018: Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Hadasit Medical Research Services and Development Ltd, H2 2019
Pipeline by Innovate Biopharmaceuticals Inc, H2 2019
Pipeline by Oasis Pharmaceuticals LLC, H2 2019
Pipeline by PeptiDream Inc, H2 2019
Pipeline by Sosei Heptares, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Hadasit Medical Research Services and Development Ltd

Innovate Biopharmaceuticals Inc

Oasis Pharmaceuticals LLC

PeptiDream Inc

Sosei Heptares

I would like to order

Product name: Proteinase Activated Receptor 2 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/P124198B448AEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P124198B448AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970